| Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance B Tegze, Z Szallasi, I Haltrich, Z Penzvalto, Z Toth, I Liko, B Győrffy PloS one 7 (2), e30804, 2012 | 71 | 2012 |
| MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer Z Pénzváltó, A Lánczky, J Lénárt, N Meggyesházi, T Krenács, ... BMC cancer 14, 1-10, 2014 | 68 | 2014 |
| Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines Z Pénzváltó, B Tegze, AM Szász, Z Sztupinszki, I Likó, A Szendrői, ... PloS one 8 (3), e59503, 2013 | 31 | 2013 |
| Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity RC Lobo, NE Hubbard, P Damonte, H Mori, Z Pénzváltó, C Pham, ... Frontiers in cell and developmental biology 4, 93, 2016 | 17 | 2016 |
| Validation of RNAi silencing efficiency using gene array data shows 18.5% failure rate across 429 independent experiments G Munkácsy, Z Sztupinszki, P Herman, B Bán, Z Pénzváltó, N Szarvas, ... Molecular Therapy-Nucleic Acids 5, 2016 | 16 | 2016 |
| Pathobiology of the 129:Stat1 −/− mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype H Mori, JQ Chen, RD Cardiff, Z Pénzváltó, NE Hubbard, L Schuetter, ... Breast cancer research 19, 1-18, 2017 | 15 | 2017 |
| A network-based target overlap score for characterizing drug combinations: high correlation with cancer clinical trial results B Ligeti, Z Penzvalto, R Vera, B Győrffy, S Pongor PLoS One 10 (6), e0129267, 2015 | 12 | 2015 |
| Biomarkers for systemic therapy in ovarian cancer Z Penzvalto, P Surowiak, B Gyorffy Current cancer drug targets 14 (3), 259-273, 2014 | 12 | 2014 |
| A syngeneic ErbB2 mammary cancer model for preclinical immunotherapy trials Z Pénzváltó, JQ Chen, CG Tepper, RR Davis, MT Silvestrini, ... Journal of mammary gland biology and neoplasia 24, 149-162, 2019 | 8 | 2019 |
| Gene expression based multigene prognostic and predictive tests in breast cancer Z Pénzváltó, Z Mihály, B Gyorffy Magyar Onkologia 53 (4), 351-359, 2009 | 6 | 2009 |
| Génexpresszió mérésén alapuló multigénes prognosztikai és prediktív előrejelzés emlőtumorokban Z Pénzváltó, Z Mihály, B Győrffy Magyar onkologia 53 (4), 351-359, 2009 | 2 | 2009 |
| Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments M Gyöngyi, S Zsófia, H Péter, B Bence, P Zsófia, S Nóra, G Balázs | | 2016 |
| A network-based target overlap score for characterizing drug combinations: High correlation with cancer clinical trial results L Balázs, P Zsófia, R Vera, G Balázs, P Sándor | | 2015 |
| Génexpresszió alapú prediktív biomarkerek a szolid tumorok szisztémás terápiájában Z Pénzváltó | | 2015 |
| Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer. B Gyorffy, A Lanczky, I Pete, C Denkert, T Krenacs, N Meggyeshazi, ... Journal of Clinical Oncology 32 (15_suppl), 5557-5557, 2014 | | 2014 |
| Identifying predictive biomarkers of carboplatin resistance in ovarian cancer Z Penzvalto, A Lanczky, B Gyorffy EUROPEAN JOURNAL OF CANCER 49, S737-S738, 2013 | | 2013 |
| Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines P Zsófia, T Bálint, SA Marcell, S Zsófia, L István, S Attila, R Schäfer, ... | | 2013 |
| Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting Z Pénzváltó, B Tegze, AM Szász, Z Sztupinszki, I Likó | | 2013 |
| Identifying resistance biomarkers against five clinically approved tyrosine kinase inhibitors in 45 cell lines. Z Pénzváltó, B Tegze, AM Szasz, R Schäfer, B Gyorffy Journal of Clinical Oncology 30 (15_suppl), e21005-e21005, 2012 | | 2012 |
| TESZTKÉRDÉSEK KREDITPONTOKÉRT P Zsófia, M Zsuzsa, G Balázs | | |
Balázs GyőrffyClarivate Highly Cited, Semmelweis, PTE, HUN-REN, ELIXIR, Hungarian Academy of SciencesE-mail megerősítve itt: ttk.mta.hu
